All In Biotech

Drug Trial Radar · NCT06545097

A Study of Cebranopadol for the Treatment of Acute Pain After Abdominoplasty

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cebranopadol for the Treatment of Moderate to Severe Acute Pain After Full Abdominoplasty

Last checked: Nov 20, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 279 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

279

Actual

Start

Sep 3, 2024

Primary completion

Dec 30, 2024

Study completion Dec 30, 2024

Sponsor

Lead sponsor
Tris Pharma, Inc.Industry
Sponsor type
Industry
First posted
Aug 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of Cebranopadol for acute pain after a Abdominoplasty.

Conditions

  • Acute Pain

Interventions

  • Cebranopadol 400 ugDrug

    Once daily

  • Cebranopadol 200 ugDrug

    Once daily on Day 2

  • PlaceboDrug

    Once daily for 2 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Outcome MeasureTime frame: 4-48 hours

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • ALLEVIATE 1 Site 001106

    Little Rock, Arkansas

  • ALLEVIATE 1 Site 001112

    Miami, Florida

  • ALLEVIATE 1 Site 001110

    Bellaire, Texas

  • ALLEVIATE 1 Site 001111

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.